According to filings with the U.S. Securities and Exchange Commission, Biostage is raising $6,005,800.00 in new funding. Sources indicate that as part of senior management President, Hong Yu played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Biostage
Biostage is a bioengineering company that is developing next-generation esophageal implants. The Companys Cellspan technology combines a proprietary, biocompatible scaffold with a patients own cells to create an esophageal implant that could potentially be used to treat pediatric esophageal atresia and other conditions that affect the esophagus. These implants have the potential to dramatically improve the quality of life for children and adults. At Biostage, we believe the future of medicine has been inside us all along.

To learn more about Biostage, visit http://www.biostage.com/

Contact:
Hong Yu, President
774-233-7300

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.